The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Participants will be randomised to receive either trilaciclib or placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Enrollment
120
Intravenous infusion
Intravenous infusion
To Compare trilaciclib to placebo on prevention of myelosuppression
Duration and occurrence of severe neutropenia
Time frame: From enrollment and 4 months after
Number of all-cause chemotherapy dose reductions
Time frame: From enrollment and 4 months after
Occurrence of granulocyte colony-stimulating factor (G-CSF) administration
Time frame: From enrollment and 4 months after
Number of hospitalizations due to myelosuppression or sepsis
Time frame: From enrollment and 4 months after
Number of febrile neutropenia
Time frame: From enrollment and 4 months after
Occurrence of red blood cell (RBC) transfusions
Time frame: From enrollment and 4 months after
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.